绥美凯可以吃多久？

(Dolutegravir tablets) is an innovative AIDS treatment drug by ViiV Healthcare, a joint venture company of GlaxoSmithKline (GSK). It is currently the only three-in-one compound drug containing dolutegravir (DTG). It is clinically suitable for the treatment of adults and adolescents over 12 years old (with a weight of at least 40 kg) infected with human immunodeficiency virus (HIV). In 2015, Suimeike (dolute abalamib tablets) submitted a clinical application in China; applied for import on January 20, 2017, and obtained priority review qualification; and was approved by the CFDA on August 1, 2017. At present, Suimeike (dolute abalamib tablets) has been approved for marketing in 50 countries and regions, and has been recommended by many European and American academic institutions and guidelines as the first-line first-line treatment for patients with HIV infection.

How long can Suimeikai be taken?

Generally speaking, as long as the patient has not developed resistance to Suimeike (Dolutea Paramid Tablets), he can continue to take it. For adults and adolescents, the recommended dose of Dolutegra is one tablet once daily. Adults or adolescents whose body weight is less than 40 kg should not be given this product because this product is a fixed-dose tablet and the dose cannot be reduced. Dolutegravir is a fixed-dose tablet and should not be used in patients requiring dose adjustments. If discontinuation or dose adjustment of one of the active ingredients is required, separate formulations of dolutegravir, abacavir, or lamivudine may be used. In these circumstances, physicians should refer to the respective product information for these medicines. If the patient misses a dose of Docetaxel, and it is more than 4 hours before the next dose, Docetaxel should be taken as soon as possible. If the next dose is less than 4 hours away, patients should not take the missed dose and simply resume their usual dosing schedule.

There are limited data on the use of dolutegravir, abacavir, and lamivudine in patients aged ≥65 years, and there is no evidence that older patients require different doses than younger adults. Taking into account age-related changes, such as decreased renal function and changes in hematological parameters, special caution is recommended when administering the drug in this age group.

Pediatric Use: The safety and effectiveness of dolutea paramilk tablets in children under 12 years of age has not been established. No data yet.